Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Fe...
Positive Results of a YG1699 Phase 2 Clinical Study Have Been Published by A Lea...
Does SGLT1 Inhibition Add to the Benefits of SGLT2 Inhibition in the Prevention ...
Chinese Government Supports High-level Reform and Increased Access to Developmen...
LEXICON ANNOUNCES FDA APPROVAL OF INPEFA™ (SOTAGLIFLOZIN) FOR TREATMENT OF HEART...
FDA's First Green Light for New Heart Failure Drug in Recent 4 Years
Dual Inhibition of SGLT1 and SGLT2 with Sotagliflozin Released Progress on AMERI...
Youngene Therapeutics Meets with Cardiologists at AHA 2022 to Discuss the Potent...
Youngene Holds a Panel Discussion with Global Diabetes Experts at the EASD 2022 ...